Program
ANXV
Its studies are mostly in Retinal Vein Occlusion, led by Annexin Pharmaceuticals AB.
Furthest: phase 2, since Jul 18, 20223 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Annexin Pharmaceuticals AB | 31 open or running | phase 2since Jul 18, 2022 | Mar 4, 2021 | none ahead |
Also a collaborator on its studies: infocus-clinical-research.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 4, 2021First study: phase 1 study in HealthyFirst studyNCT04850339 · 46 enrolled · Netherlands
- Jul 18, 2022Phase 2 study in Retinal Vein OcclusionNCT05532735 · 16 enrolled · United States
- Sep 16, 2025Phase 2 study in Retinal Vein OcclusionNCT07259928 · 12 planned · United Kingdom
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07259928Retinal Vein Occlusion · United Kingdom | 2 | Recruiting | Jul 2026 | 12 |
| NCT05532735Retinal Vein Occlusion · United States | 2 | Completed | Jul 17, 2024 | 16 |
| NCT04850339Healthy · Netherlands | 1 | Completed | Oct 27, 2021 | 46 |
How it is read
Names in the registry
- “ANXV”, 3 entries
Conditions, from the studies’ own filings
- Retinal Vein Occlusion, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.